Similar trends can be seen in non‐small‐cell lung cancer (NSCLC; Fig. 5B), where patients with high‐IP expression respond better to the anti‐PD‐1 treatment (Nivolumab). This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.